Lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction: from physiology to clinical aspects

References

• Kirby M, Chapple C, Jackson G, et al. Erectile dysfunction and lower urinary tract symptoms: a consensus on the importance of co-diagnosis. Int J Clin Pract. 2013;67:606–618.
   PubMed Web of Science ®Google Scholar
• Amano T, Earle C, Imao T, et al. Administration of daily 5 mg tadalafil improves endothelial function in patients with benign prostatic hyperplasia. Aging Male. 2017;22:1–6.
   Web of Science ®Google Scholar
• Ko WJ, Han HH, Ham WS, et al. Daily use of sildenafil 50mg at night effectively ameliorates nocturia in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: an exploratory multicenter, double-blind, randomized, placebo-controlled study. Aging Male. 2017;20:81–88.
   PubMed Web of Science ®Google Scholar
• Patel DV, Halls J, Patel U. Investigation of erectile dysfunction. Br J Radiol. 2012;85:69–78.
   PubMed Web of Science ®Google Scholar
• Rajfer JAW, Bush PA, Dorney FJ, et al. Nitric oxide as a mediator of smooth muscle relaxation of the corpus cavernosum in response to nonadrenergic-noncholinergic neurotransmission. N Engl J Med. 1992;326:90–94.
   PubMed Web of Science ®Google Scholar
• Burnett AL. Nitric oxide control of lower genitourinary tract functions: a review. Urology. 1995;45:1071–1083.
   PubMed Web of Science ®Google Scholar
• Reynard JM. Does anticholinergic medication have a role for men with lower urinary tract symptoms/benign prostatic hyperplasia either alone or in combination with other agents? Curr Opin Urol. 2004;14:13–16.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol. 2006;49:651–658.
   PubMed Web of Science ®Google Scholar
• Hashim H, Abrams P. Overactive bladder: an update. Curr Opin Urol. 2007;17:231–236.
   PubMed Web of Science ®Google Scholar
• Parsons JK. Lifestyle factors, benign prostatic hyperplasia, and lower urinary tract symptoms. Curr Opin Urol. 2011;21:1–4.
   PubMed Web of Science ®Google Scholar
• Roosen A, Chapple CR, Dmochowski RR, et al. A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol. 2009;56:810–819.
   PubMed Web of Science ®Google Scholar
• Park HJ, Won J, Sorsaburu S, et al. Urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) and LUTS/BPH with erectile dysfunction in Asian men: a systematic review focusing on tadalafil. World J Mens Health. 2013;31:193–207.
   PubMedGoogle Scholar
• Andersson KE, De Groat WC, McVary KT, et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn. 2011;30:292–301.
   PubMed Web of Science ®Google Scholar
• Gacci M, Eardley I, Giuliano F, et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2011;60:809–825.
   PubMed Web of Science ®Google Scholar
• Kolpakov V, Di Sciullo A, Nasuti M, et al. Reduced smooth muscle cell regeneration in Yoshida (YOS) spontaneously hypercholesterolemic rats. Atherosclerosis 1994;111:227–236.
   PubMed Web of Science ®Google Scholar
• Azadzoi KM, Tarcan T, Siroky MB, et al. Atherosclerosis-induced chronic ischemia causes bladder fibrosis and non-compliance in the rabbit. J Urol. 1999;161:1626–1635.
   PubMed Web of Science ®Google Scholar
• Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol. 2005;96:85–93.
   PubMed Web of Science ®Google Scholar
• Azadzoi KM, Babayan RK, Kozlowski R, et al. Chronic ischemia increases prostatic smooth muscle contraction in the rabbit. J Urol. 2003;170:659–663.
   PubMed Web of Science ®Google Scholar
• Berger AP, Deibl M, Leonhartsberger N, et al. Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction. BJU Int. 2005;96:1073–1078.
   PubMed Web of Science ®Google Scholar
• Giuliano F, Ückert S, Maggi M, et al. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol. 2013;63:506–516.
   PubMed Web of Science ®Google Scholar
• McVary KT. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol. 2005;47:838–845.
   PubMed Web of Science ®Google Scholar
• Gratzke C, Bachmann A, Descazeaud A, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015;67:1099–1109.
   PubMed Web of Science ®Google Scholar
• Rosen R, Carson C, Giuliano F. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol. 2005;47:824–837.
   PubMed Web of Science ®Google Scholar
• McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185:1793–1803.
   PubMed Web of Science ®Google Scholar
• Arrighi HM, Guess HA, Metter EJ, et al. Symptoms and signs of prostatism as risk factors for prostatectomy. Prostate. 1990;16:253–261.
   PubMed Web of Science ®Google Scholar
• Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol. 1997;158:481–487.
   PubMed Web of Science ®Google Scholar
• Capogrosso P, Colicchia M, Ventimiglia E, et al. One patient out of four with newly diagnosed erectile dysfunction is a young man — worrisome picture from the everyday clinical practice. J Sex Med. 2013;10:1833–1841.
   PubMed Web of Science ®Google Scholar
• Salonia A, Castagna G, Saccà A, et al. Is erectile dysfunction a reliable proxy of general male health status? The case for the International Index of Erectile Function–Erectile Function domain. J Sex Med. 2012;9:2708–2715.
   PubMed Web of Science ®Google Scholar
• Yao F, Liu L, Zhang Y, et al. Erectile dysfunction may be the first clinical sign of insulin resistance and endothelial dysfunction in young men. Clin Res Cardiol. 2013;102:645–651.
   PubMed Web of Science ®Google Scholar
• Ludwig W, Phillips M. Organic causes of erectile dysfunction in men under 40. Urol Int. 2014;92:1–6.
   PubMed Web of Science ®Google Scholar
• Sanders SA, Hill BJ, Janssen E, et al. General erectile functioning among young, heterosexual men who do and do not report condom-associated erection problems (CAEP). J Sex Med. 2015;12:1897–1904.
   PubMed Web of Science ®Google Scholar
• Papagiannopoulos D, Khare N, Nehra A. Evaluation of young men with organic erectile dysfunction. Asian J Androl. 2015;17:11–16.
   PubMed Web of Science ®Google Scholar
• Nehra A, Goldstein I, Pabby A, et al. Mechanisms of venous leakage: a prospective clinicopathological correlation of corporeal function and structure. J Urol. 1996;156:1320–1329.
   PubMed Web of Science ®Google Scholar
• Leungwattanakij S, Pummangura N, Ratana-Olarn K. Penile enhancement using a porcine small intestinal submucosa graft in a rat model. Int J Impot Res. 2006;18:39–43.
   PubMed Web of Science ®Google Scholar
• Ferrini MG, Davila HH, Kovanecz I, et al. Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat. Urology. 2006;68:429–435.
   PubMed Web of Science ®Google Scholar
• Mulhall JP, Müller A, Donohue JF, et al. The functional and structural consequences of cavernous nerve injury are ameliorated by sildenafil citrate. J Sex Med. 2008;5:1126–1136.
   PubMed Web of Science ®Google Scholar
• Ferrini MG, Kovanecz I, Sanchez S, et al. Fibrosis and loss of smooth muscle in the corpora cavernosa precede corporal veno-occlusive dysfunction (CVOD) induced by experimental cavernosal nerve damage in the rat. J Sex Med. 2009;6:415–428.
   PubMed Web of Science ®Google Scholar
• Yafi FA, Jenkins L, Albersen M, et al. Erectile dysfunction. Nat Rev Dis Primers. 2016;4:16003.
   Web of Science ®Google Scholar
• Barry MJ, Fowler FJ Jr, O’Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 1992;148:1549–1557.
   Google Scholar
• Grimm RH Jr, Grandits GA, Prineas RJ, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women: treatment of mild hypertension study (TOMHS). Hypertension. 1997;29:8–14.
   PubMed Web of Science ®Google Scholar
• Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822–830.
   PubMed Web of Science ®Google Scholar
• Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the international index of erectile function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11:319–326.
   PubMed Web of Science ®Google Scholar
• Althof SE, Rosen RC, Perelman MA, et al. Standard operating procedures for taking a sexual history. J Sex Med. 2013;10:26–35.
   PubMed Web of Science ®Google Scholar
• Ghanem HM, Salonia A, Martin-Morales A. SOP: physical examination and laboratory testing for men with erectile dysfunction. J Sex Med. 2013;10:108–110.
   PubMed Web of Science ®Google Scholar
• Aktas BK, Gokkaya CS, Bulut S, et al. Impact of metabolic syndrome on erectile dysfunction and lower urinary tract symptoms in benign prostatic hyperplasia patients. Aging Male. 2011;14:48–52.
   PubMed Web of Science ®Google Scholar
• Demir O, Akgul K, Akar Z, et al. Association between severity of lower urinary tract symptoms, erectile dysfunction and metabolic syndrome. Aging Male. 2009;12:29–34.
   PubMed Web of Science ®Google Scholar
• Yassin AA, Saad F, Gooren LJ. Metabolic syndrome, testosterone deficiency and erectile dysfunction never come alone. Andrologia. 2008;40:259–264.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Fujimura T, Nagata M, et al. Association between lower urinary tract symptoms and sexual dysfunction assessed using the core lower urinary tract symptom score and International Index of Erectile Function-5 questionnaires. Aging Male. 2012;15:111–114.
   PubMed Web of Science ®Google Scholar
• Gacci M, Andersson KE, Chapple C, et al. Latest evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2016;70:124–133.
   PubMed Web of Science ®Google Scholar
• Yassin A, Saad F, Hoesl CE, et al. Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS-implications for clinical practice. Andrologia. 2006;38:1–12.
   PubMed Web of Science ®Google Scholar
• Favilla V, Russo GI, Privitera S, et al. Impact of combination therapy 5-alpha reductase inhibitors (5-ARI) plus alpha-blockers (AB) on erectile dysfunction and decrease of libido in patients with LUTS/BPH: a systematic review with meta-analysis. Aging Male. 2016;19:175–181.
   PubMed Web of Science ®Google Scholar
• Haider KS, Haider A, Doros G, et al. Long-term testosterone therapy improves urinary and sexual function, and quality of life in men with hypogonadism: results from a propensity matched subgroup of a controlled registry study. J Urol. 2018;199:257–265.
   PubMed Web of Science ®Google Scholar
• Yassin A, Nettleship JE, Talib RA, et al. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Aging Male. 2016;19:64–69.
   PubMed Web of Science ®Google Scholar